Tyme Technologies Inc (NASDAQ:TYME) Major Shareholder Michael Demurjian Sells 20,000 Shares

Tyme Technologies Inc (NASDAQ:TYME) major shareholder Michael Demurjian sold 20,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $1.14, for a total transaction of $22,800.00. Following the sale, the insider now owns 26,070,521 shares of the company’s stock, valued at approximately $29,720,393.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Michael Demurjian also recently made the following trade(s):

  • On Monday, November 25th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.13, for a total transaction of $22,600.00.
  • On Monday, November 18th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.09, for a total value of $21,800.00.
  • On Monday, November 11th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.16, for a total value of $23,200.00.
  • On Monday, November 4th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.27, for a total value of $25,400.00.
  • On Monday, October 28th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.36, for a total value of $27,200.00.
  • On Monday, October 21st, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.40, for a total value of $28,000.00.
  • On Monday, October 14th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $92.98, for a total value of $1,859,600.00.
  • On Monday, October 7th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.35, for a total transaction of $27,000.00.
  • On Tuesday, October 1st, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.42, for a total value of $28,400.00.
  • On Monday, September 23rd, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.67, for a total value of $33,400.00.

NASDAQ:TYME traded down $0.01 during midday trading on Tuesday, hitting $1.12. 226,117 shares of the stock were exchanged, compared to its average volume of 622,971. The company has a market capitalization of $126.50 million, a price-to-earnings ratio of -3.50 and a beta of 0.34. Tyme Technologies Inc has a one year low of $0.92 and a one year high of $4.64. The business has a 50-day moving average price of $1.25 and a two-hundred day moving average price of $1.25.

Tyme Technologies (NASDAQ:TYME) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. As a group, analysts forecast that Tyme Technologies Inc will post -0.21 earnings per share for the current fiscal year.

TYME has been the subject of a number of recent analyst reports. ValuEngine raised Tyme Technologies from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. HC Wainwright started coverage on Tyme Technologies in a research report on Monday, August 12th. They set a “buy” rating for the company. Finally, Zacks Investment Research raised Tyme Technologies from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research note on Friday, November 8th.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp raised its holdings in shares of Tyme Technologies by 5.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 306,199 shares of the company’s stock worth $374,000 after purchasing an additional 17,173 shares in the last quarter. Paloma Partners Management Co bought a new stake in Tyme Technologies during the second quarter worth approximately $238,000. Perkins Capital Management Inc. boosted its holdings in Tyme Technologies by 77.0% during the third quarter. Perkins Capital Management Inc. now owns 142,500 shares of the company’s stock worth $170,000 after buying an additional 62,000 shares in the last quarter. Morgan Stanley boosted its holdings in Tyme Technologies by 187.8% during the second quarter. Morgan Stanley now owns 139,579 shares of the company’s stock worth $170,000 after buying an additional 91,081 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Tyme Technologies in the third quarter worth approximately $71,000. Institutional investors and hedge funds own 12.93% of the company’s stock.

Tyme Technologies Company Profile

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Further Reading: Compound Interest

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.